3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
8
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Hodgkin Disease
27
Lymphoma
22
Hematologic Diseases
20
Lymphoma, Large-Cell, Anaplastic
16
Lymphoma, Non-Hodgkin
11
Recurrence
5
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, B-Cell
4
Lymphoma, T-Cell, Cutaneous
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Melanoma
2
Lymphoma, Primary Cutaneous Anaplastic Large Cell
2
Dendritic Cell Sarcoma, Interdigitating
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Kaposi
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphomatoid Papulosis
1
Interventions
hypericin
4
zanolimumab
3
mogamulizumab
3
cobomarsen
3
Vorinostat
3
Bexarotene
3
denileukin diftitox
2
Vitamin B 12
2
Panobinostat
2
Folic Acid
2
Amines
2
A-dmDT390-bisFv(UCHT1) protein
2
10-propargyl-10-deazaaminopterin
2
talimogene laherparepvec
1
resminostat
1
ontuxizumab
1
navitoclax
1
forodesine
1
TTI-621
1
Radiation
1
N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide
1
Methotrexate
1
Mechlorethamine
1
MAC-ST-001
1
Interleukin-12 Subunit p35
1
Fentanyl
1
Fenretinide
1
Duration of Therapy
1
Drug Therapy
1
Brentuximab Vedotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Mycosis Fungoides
×
Brentuximab Vedotin
×
Clear all
NCT01578499
2021-01-05
ALCANZA
Takeda
Phase 3
Completed
131 enrolled
24 charts